IceCure Medical (NASDAQ:ICCM) Shares Down 3.3%

IceCure Medical Ltd (NASDAQ:ICCM) dropped 3.3% on Wednesday . The stock traded as low as $1.17 and last traded at $1.17. Approximately 287,875 shares changed hands during trading, a decline of 52% from the average daily volume of 601,639 shares. The stock had previously closed at $1.21.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on ICCM shares. Alliance Global Partners lifted their target price on shares of IceCure Medical from $1.90 to $2.90 and gave the company a “buy” rating in a research note on Wednesday, March 20th. HC Wainwright reiterated a “buy” rating and issued a $3.00 price objective on shares of IceCure Medical in a research report on Tuesday, April 16th.

IceCure Medical Trading Down 3.3 %

The business’s 50-day simple moving average is $1.23 and its 200-day simple moving average is $1.14. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.08 and a current ratio of 3.66. The company has a market capitalization of $53.38 million, a price-to-earnings ratio of -3.55 and a beta of 0.70.

IceCure Medical (NASDAQ:ICCM) last announced its quarterly earnings data on Wednesday, April 3rd. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.01. The firm had revenue of $1.26 million for the quarter. IceCure Medical had a negative net margin of 453.76% and a negative return on equity of 86.96%. During the same period in the previous year, the business posted ($0.11) earnings per share. On average, research analysts expect that IceCure Medical Ltd will post -0.28 earnings per share for the current fiscal year.

IceCure Medical Company Profile

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a single probe system for the treatment of breast tumors; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.